Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

malignant testicular germ cell tumor - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

malignant testicular germ cell tumor

MONDO:0003510

Also known as:testicular cancermalignant germ cell neoplasm of testismalignant germ cell neoplasm of the testis

Find Clinical TrialsTrials

Overview

A malignant tumor predominantly affecting young men and often associated with cryptorchidism. Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor.

TreatmentsNo approved treatments · 1 in pipeline

Clinical Trials53 registered · 32 recruiting

Diagnosis

Biomarker and diagnostic research for malignant testicular germ cell tumor has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for malignant testicular germ cell tumor. An additional 1 compound holds orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for malignant testicular germ cell tumor, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for malignant testicular germ cell tumor. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

53 clinical trials registered, 32 recruiting. Interventions under study include other interventions, drug therapy, procedural interventions, and medical devices. Pipeline includes 1 PHASE3, 4 PHASE2, 7 PHASE1. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06814496](https://clinicaltrials.gov/study/NCT06814496)

Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 1:12 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→Are any of the 53 active clinical trials a good fit for my situation?
→What is the current development status of Ifosfamide, and when might it become available?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Research summaries	68	41%
Disease patterns and progression	37	22%
Laboratory research	20	12%
Testing and diagnosis research	13	8%
Other research	10	6%
Patient case studies	10	6%
Clinical study results	4	2%
New treatment approaches	3	2%

malignant testicular germ cell tumor

Overview

Diagnosis

Treatment

Orphan Drug Designations

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications